The stock of Black Diamond Therapeutics Inc (BDTX) has seen a 11.90% increase in the past week, with a 29.07% gain in the past month, and a -2.97% decrease in the past quarter. The volatility ratio for the week is 8.10%, and the volatility levels for the past 30 days are at 9.09% for BDTX. The simple moving average for the last 20 days is 20.35% for BDTX’s stock, with a simple moving average of -35.42% for the last 200 days.
Is It Worth Investing in Black Diamond Therapeutics Inc (NASDAQ: BDTX) Right Now?
The 36-month beta value for BDTX is at 2.52. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for BDTX is 42.91M, and currently, shorts hold a 17.46% of that float. The average trading volume for BDTX on January 31, 2025 was 758.40K shares.
BDTX) stock’s latest price update
Black Diamond Therapeutics Inc (NASDAQ: BDTX)’s stock price has soared by 10.12 in relation to previous closing price of 2.52. Nevertheless, the company has seen a gain of 11.90% in its stock price over the last five trading days. seekingalpha.com reported 2024-12-30 that Black Diamond Therapeutics, Inc.’s BDTX-1535 showed a promising 42% ORR in Phase 2 trials for recurrent EGFR-mutant NSCLC, which addresses treatment-resistant mutations. The MasterKey platform enables targeting entire families of oncogenic mutations, offering potential solutions for underserved cancer populations like non-classical NSCLC and glioblastoma. BDTX’s $112.7 million cash reserves will support operations through Q2 2026. Restructuring efforts will prioritize high-value programs like BDTX-1535.
Analysts’ Opinion of BDTX
Many brokerage firms have already submitted their reports for BDTX stocks, with Raymond James repeating the rating for BDTX by listing it as a “Outperform.” The predicted price for BDTX in the upcoming period, according to Raymond James is $20 based on the research report published on July 31, 2024 of the previous year 2024.
Stifel gave a rating of “Buy” to BDTX, setting the target price at $10 in the report published on June 30th of the previous year.
BDTX Trading at 17.08% from the 50-Day Moving Average
After a stumble in the market that brought BDTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.77% of loss for the given period.
Volatility was left at 9.09%, however, over the last 30 days, the volatility rate increased by 8.10%, as shares surge +29.21% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +5.53% upper at present.
During the last 5 trading sessions, BDTX rose by +11.49%, which changed the moving average for the period of 200-days by -47.03% in comparison to the 20-day moving average, which settled at $2.31. In addition, Black Diamond Therapeutics Inc saw 29.67% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BDTX starting from Versant Venture Capital VI, L., who sale 221,600 shares at the price of $6.32 back on Aug 28 ’24. After this action, Versant Venture Capital VI, L. now owns 3,726,341 shares of Black Diamond Therapeutics Inc, valued at $1,400,556 using the latest closing price.
David Epstein, the Former Employer of Black Diamond Therapeutics Inc, proposed sale 50,000 shares at $6.20 during a trade that took place back on Jul 31 ’24, which means that David Epstein is holding shares at $310,000 based on the most recent closing price.
Stock Fundamentals for BDTX
Current profitability levels for the company are sitting at:
- -16.62 for the present operating margin
- 0.93 for the gross margin
The net margin for Black Diamond Therapeutics Inc stands at -14.94. The total capital return value is set at -0.69. Equity return is now at value -63.09, with -47.12 for asset returns.
Based on Black Diamond Therapeutics Inc (BDTX), the company’s capital structure generated 0.19 points at debt to capital in total, while cash flow to debt ratio is standing at -2.66. The debt to equity ratio resting at 0.24. The interest coverage ratio of the stock is -118.6.
Currently, EBITDA for the company is -86.02 million with net debt to EBITDA at 0.01. When we switch over and look at the enterprise to sales, we see a ratio of 31.36. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.55.
Conclusion
In conclusion, Black Diamond Therapeutics Inc (BDTX) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
